Previous 10 | Next 10 |
– Other Studies Highlight Impact of Linaclotide in Adult and Pediatric Populations, Highlight Disease Burden – Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, presented new findings during the 2022 Digestive Disease Week ...
– Data to be featured in two oral presentations and six posters – – CEO Tom McCourt to receive American Society for Gastrointestinal Endoscopy (ASGE) President’s Award at meeting – Ironwood Pharmaceuticals, Inc . (Nasdaq: IRWD), a...
Ironwood Pharmaceuticals, Inc. (IRWD) Q1 2022 Earnings Conference Call May 5, 2022 08:30 ET Company Participants Matt Roache - Director, Investor Relations Tom McCourt - Chief Executive Officer Mike Shetzline - Chief Medical Officer Sravan Emany - Chief Financial Officer Conference Call Parti...
Ironwood Pharmaceuticals press release (NASDAQ:IRWD): Q1 Non-GAAP EPS of $0.21. Revenue of $98M. FY22 financial guidance maintained. For further details see: Ironwood Pharmaceuticals Non-GAAP EPS of $0.21, revenue of $98M
– LINZESS ® (Iinaclotide) prescription demand growth increased 11% year-over-year; LINZESS U.S. net sales of $232 million, an increase of 8% year-over-year – – Total revenue of $98 million; U.S. LINZESS collaboration revenue of $94 million &...
Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is $0.26 (+8.3% Y/Y) and the consensus Revenue Estimate is $96.62M (+8.7% Y/Y). Over the last 2 years, IRWD has beaten EPS estimates 75% of ...
Positive interim response for appeal of XPHOZAH received for CKD-PH patients; Advisory Committee could possibly turn things around for possible FDA approval. IBSRELA launched commercially in the United States on April 4, 2022; IBS-C market proven with revenues generated by sales of Li...
Piper Sandler has initiated Ironwood Pharmaceuticals (NASDAQ:IRWD) at overweight citing the success of the company's irritable bowel syndrome drug Linzess (linaclotide). The firm has a $16 price target (~36% upside based on Thursday's close). Analyst David Amsellem said that Linzess has three...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its first quarter 2022 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, May 5, 2022. Individuals interested in participating in the call should dial (888) 330-2384 (U.S. and ...
PBE is neither suitable for income seekers, nor for long term investors. Despite being a Genomic revolution fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better biotechnology ETFs of similar nature are available in the market. For f...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-22 07:00:07 ET Mohit Bansal from Wells Fargo issued a price target of $14.00 for IRWD on 2024-05-22 05:13:00. The adjusted price target was set to $14.00. At the time of the announcement, IRWD was trading at $6.78. The overall price target consensus is at $16.00 ...